Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Akershus
• Collaborator: Solvay Pharmaceuticals
• Treatments: Levodopa

Criteria

Inclusion Criteria:

• Clinical diagnosis of of idiopathic Parkinsons disease

• Motor fluctuations despite optimised per oral treatment

Exclusion Criteria:

• Severe dementia, confusion, psychosis or depression

• Patients with contraindications against levodopa treatment